Open Innovation at Boehringer Ingelheim
Open Innovation at Boehringer Ingelheim
Search
Vienna
Vienna is a cornerstone within the company’s global R&D network, with a special focus on cancer research. On top of that, it is also a hub for biopharmaceutical development and production.
BI Presents Combination Data of Tiotropium + Olodaterol | Boehringer Ingelheim US
BI presented the first data from the pivotal Phase III TONADO™ 1&2 studies for the FDC of tiotropium plus olodaterol delivered via the Respimat® inhaler.
Scleroderma
Scleroderma
Biopharma Contract Manufacturing
Biopharma Contract Manufacturing
Fighting Non-Communicable Diseases | Boehringer Ingelheim US
Read more on Boehringer Ingelheim's new NCD initiative, aiming to reduce NCD prevalence and capture the impact of our product portfolio for our patients.
Update on sNDA for fibrosing ILD in children and adolescents
Press release providing an update on FDA review of sNDA in children and adolescents with fibrosing interstitial lung disease (ILD)
BI Beyond Borders: Science, Collaboration, Geography | BI US
Read more on how the Company’s ‘radar’ for the next big wave of innovation, the RBB team, is tasked with exploring emerging science and technologies.
Partnering for Innovative Pet Therapeutics
Partnering for Innovative Pet Therapeutics
Partnering-Oncology-Cancer-Imm-HP.pdf
Colorectal_Cancer_Infographic.pdf
Boehringer Ingelheim sees positive business momentum in 2020 despite impact of COVID-19
Boehringer Ingelheim sees positive business momentum in 2020 despite impact of COVID-19
STIOLTO® RESPIMAT® (tiotropium bromide) Available in US | BI US
Read more about the newly available medication for COPD, STIOLTO RESPIMAT, proven to support both treatment and management of the disease.
Interchangeable Biosimilar Now on Express Scripts® Formulary
Boehringer Ingelheim’s Interchangeable biosimilar now included on Express Scripts National Preferred Formulary
Patients with a rare and aggressive form of liposarcoma need treatment advances
Patients with a rare and aggressive form of liposarcoma need treatment advances
Low-WAC interchangeable biosimilar is now available
Adalimumab-adbm, our interchangeable biosimilar to Humira, now available at a low wholesale acquisition cost.
Cyltezo®, first and only FDA-approved Interchangeable biosimilar to Humira®, now commercially available in the U.S.
Cyltezo®, first and only FDA-approved Interchangeable biosimilar to Humira®, now commercially available in the U.S.
First half of 2023: Boehringer Ingelheim sees strong growth and expansion in key therapy areas
Currency-adjusted net sales rose by 9.7 percent to 13.5 billion USD.
Financial year 2018
Financial year 2018
Boehringer Ingelheim and Partners to Accelerate Development of First-In-Class Gene Therapy for Patients with Cystic Fibrosis
Boehringer Ingelheim and Partners to Accelerate Development of First-In-Class Gene Therapy for Patients with Cystic Fibrosis
NASH
NASH
New agreement with Quallent expands biosimilar access
Boehringer Ingelheim enters private label agreement for biosimilar
FDA approves additional formulation of biosimilar
US FDA approves additional formulation of Cyltezo® (adalimumab-adbm). See Important Safety Information including Boxed Warning, Prescribing Information, Medication Guide and Instructions for Use.
Our Science Focus
Our Science Focus
We support non-linear career paths.
Emmanuelle Clerisme-Beaty talks about making breakthroughs in the rare disease space.“I’m here to let patients know that they're not alone”